A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment

Lee, Ho-Sung; Lee, In-Hee; Kang, Kyungrae; Park, Sang-In; Moon, Seung-Joon; Lee, Chol Hee; Lee, Dae-Yeon

doi:https://doi.org/10.1155/2021/3919143

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Abbreviations Data Availability Conflicts of Interest Acknowledgments Supplementary Materials References Copyright Related Articles

Special Issue

Herbal Medicine for Prevention and Therapy in Breast Cancer

View this Special Issue

Research Article | Open Access

Volume 2021 | Article ID 3919143 | https://doi.org/10.1155/2021/3919143

A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment

Ho-Sung Lee,^1,2In-Hee Lee,¹Kyungrae Kang,²Sang-In Park,³Seung-Joon Moon,²Chol Hee Lee,²and Dae-Yeon Lee^1,2

Academic Editor: Azis Saifudin

Received29 May 2020

Revised25 Jan 2021

Accepted29 Jan 2021

Published06 Feb 2021

Abstract

Herbal medicines have drawn considerable attention with regard to their potential applications in breast cancer (BC) treatment, a frequently diagnosed malignant disease, considering their anticancer efficacy with relatively less adverse effects. However, their mechanisms of systemic action have not been understood comprehensively. Based on network pharmacology approaches, we attempted to unveil the mechanisms of FDY003, an herbal drug comprised of Lonicera japonica Thunberg, Artemisia capillaris Thunberg, and Cordyceps militaris, against BC at a systemic level. We found that FDY003 exhibited pharmacological effects on human BC cells. Subsequently, detailed data regarding the biochemical components contained in FDY003 were obtained from comprehensive herbal medicine-related databases, including TCMSP and CancerHSP. By evaluating their pharmacokinetic properties, 18 chemical compounds in FDY003 were shown to be potentially active constituents interacting with 140 BC-associated therapeutic targets to produce the pharmacological activity. Gene ontology enrichment analysis using g:Profiler indicated that the FDY003 targets were involved in the modulation of cellular processes, involving the cell proliferation, cell cycle process, and cell apoptosis. Based on a KEGG pathway enrichment analysis, we further revealed that a variety of oncogenic pathways that play key roles in the pathology of BC were significantly enriched with the therapeutic targets of FDY003; these included PI3K-Akt, MAPK, focal adhesion, FoxO, TNF, and estrogen signaling pathways. Here, we present a network-perspective of the molecular mechanisms via which herbal drugs treat BC.

1. Introduction

Breast cancer (BC) is a common female malignancy and a cause of mortality globally [1]. The genetic and epigenetic dysregulations in multiple cancer-associated genes and their key oncogenic signalings are implicated in the pathology of BC; these include the phosphoinositide 3-kinase- (PI3K-) Akt, tumor necrosis factor (TNF), forkhead box O (FoxO), erythroblastic leukemia viral oncogene homolog (ErbB), vascular endothelial growth factor (VEGF), hypoxia-inducible factor- (HIF-) 1, estrogen, p53, focal adhesion, and mitogen-activated protein kinase (MAPK) pathways [2–4]. Currently, chemotherapy, molecular-targeted therapy, and endocrine therapy are the major pharmacological approaches for BC treatment [5–10]. However, the long-term and frequent use of the aforementioned therapeutic drugs may induce toxic events that deteriorate quality of life of cancer patients, including gastrointestinal dysfunction, fatigue, peripheral neuropathy, immunosuppression and myelosuppression, cardiotoxicity, and osteoporosis [11–18]. In addition, the pharmacological efficacy of most molecular-targeted agents often falls short of expectations because of their limited capacity to therapeutically modulate the cancerous activities of various oncogenic cellular components [19]. These issues emphasize the need for anticancer agents that can pharmacologically regulate multiple oncogenes and pathways with safety. Herbal drugs are multicomponent therapeutics that elicit their pharmacological effects via multiple chemical compounds that target diverse disease-related genes, proteins, and pathways [20, 21]. Herbal medicines have attracted much attention due to their promising anticancer effects, reduced toxicities, and lower side effects [20, 21]. Previous clinical research studies have further shown that the use of herbal drugs can improve the tumor response, survival, health status, and quality of life of patients undergoing cancer therapy [22, 23].

FDY003 is an herbal formula composed of three herbal medicines [24, 25], namely, Lonicera japonica Thunberg (LjT), Artemisia capillaris Thunberg (AcT), and Cordyceps militaris (Cm), that have been reported to exert prominent anticancer effects in various cancer types [26–35]. It has been shown that FDY003 is a potent inhibitor of proliferation while promoting the apoptotic death of cancer cells and tumors [24, 25]. These activities involve regulation of key modulators of cell cycle and apoptosis, such as p53, p21, caspase-3, and Bcl-2-associated X protein (Bax) [24]. However, the molecular mechanisms of FDY003 against BC at the systemic level remain unclear.

Network pharmacology is a multidisciplinary research approach that uncovers complex disease mechanisms and can be used to formulate promising treatment strategies based on a systems perspective [36–39]. The interdisciplinary methodology integrates diverse scientific fields, such as medicine, pharmacology, network biology, systems biology, and computer science [36–39]. Network pharmacology has been demonstrated to be an efficient tool for the acquisition of comprehensive and systematic insights into the “multicompound, multitarget, multipathway” polypharmacological properties of herbal medicines, and it is extensively used to explore the active chemical compounds of herbal drugs and their therapeutic targets responsible for their pharmacological activities [36–39]. Network pharmacology investigates how associated systematic mechanisms are regulated through interactions among various key components and targets [36–39]. Here, we attempted to unravel the molecular mechanisms of anti-BC effects of FDY003 based on network pharmacology approaches.

2. Materials and Methods

2.1. Cell Culture

The MCF-7, MDA-MB-453, and MDA-MB-231 human BC cell lines were purchased from the Korean Cell Line Bank (Seoul, Korea). The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, WELGENE Inc., Daegu, Korea) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific Inc., Waltham, MA, USA). The cultured cells were maintained in a humidified atmosphere with 5% CO₂ at 37°C.

2.2. Preparation of FDY003 Herbal Formula

The preparation of FDY003 was conducted as previously described [25]. In brief, the raw herbal constituents of FDY003 were obtained from Green Myeong-Poom Pharm. Co., Ltd. (Namyangju, Korea). The dried plant materials of LjT (4.16 g), AcT (6.25 g), and Cm (6.25 g) were ground, added to 70% ethanol (500 mL), and subjected to reflux extraction at 80°C for 3 h. Then, the herbal extract was filtered through a 1 μm pore filter (Hyundai Micro, Seoul, Korea) and successively purified with 80% and 90% ethanol. The resulting solution was lyophilized at −80°C. The samples were stored at −20°C and then dissolved in distilled water before the experiments.

2.3. Cell Viability Assay

The cell viability assay was performed following the previous procedures [25]. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Sigma-Aldrich Inc. (St. Louis, MO, USA). Cell viability was measured using the MTT assay. The cells were seeded in 96-well plates (5.0 × 10⁴ cells per well) and then treated with the indicated drugs for 72 h in a 5% CO₂ incubator at 37°C. Subsequently, MTT solution (200 μL) was added to each well, and the cells were further incubated for 2 h. Thereafter, the resulting formazan crystals were dissolved in dimethyl sulfoxide, and the absorbance was read with an Epoch 2 Microplate Spectrophotometer at 550 nm (BioTek, Winooski, VT, USA).

2.4. Exploration of Active Chemical Compounds

Comprehensive information on the phytochemical components of FDY003 was integrated from traditional Chinese medicine systems pharmacology (TCMSP) and anticancer herbs database of systems pharmacology (CancerHSP) databases [40, 41]. To determine the bioactive compounds of FDY003, we assessed the key absorption, distribution, metabolism, and excretion (ADME) pharmacokinetic parameters (i.e., oral bioavailability (OB), drug-likeness (DL), and Caco-2 permeability) of chemical constituents obtained from the TCMSP database [40]. OB, a pivotal consideration in drug development, is a measurement of the rate, fraction, and extent of an orally administered drug that reaches the expected site of drug action [40, 42]. Caco-2 permeability is a parameter widely used for the evaluation of the intestinal absorption rate and extent of a given substance using Caco-2 human intestinal epithelial cells [40, 43–45]. In general, drug molecules with a Caco-2 permeability less than −0.4 are considered not permeable across the epithelium of intestines [40, 46, 47]. DL is an indicator that is used to assess whether a compound has the potential to be developed into a drug with respect to its physical and chemical properties; it is calculated based on the Tanimoto coefficient and relevant molecular descriptors [40, 48]. A chemical compound is considered active if it meets the following criteria: OB ≥ 30%, Caco-2 permeability ≥ −0.4, and DL ≥ 0.18 [37, 40, 49, 50].

2.5. Target Identification for the Active Compounds

Molecular targets of the bioactive compounds of FDY003 were determined using comprehensive information regarding chemical-protein interactions obtained from various relevant databases, including Search Tool for Interactions of Chemicals (STITCH) 5 [51], SwissTargetPrediction [52, 53], PharmMapper [54], and Similarity Ensemble Approach (SEA) [55]. We also used in silico models, such as systematic drug targeting tool (SysDT) [56] and weighted ensemble similarity (WES) algorithm [57], for target identification according to previously described procedures [58–63]. Human genes/proteins related to the pathology of BC were obtained from the following databases: Therapeutic Target Database (TTD) [64], GeneCards [65], Comparative Toxicogenomics Database (CTD) [66], DisGeNET [67], Human Genome Epidemiology (HuGE) Navigator [68], Online Mendelian Inheritance in Man (OMIM) [69], Pharmacogenomics Knowledgebase (PharmGKB) [70], and DrugBank [71].

2.6. Network Construction

The herbal medicine-bioactive compound (H-C) and bioactive compound-target (C-T) networks were generated by connecting the three herbal constituents of FDY003 with the bioactive compounds and the bioactive compounds with the targets. The target-pathway (T-P) network was generated by connecting the targets with relevant biological pathways. The protein-protein interaction (PPI) network was generated based on the interactions between the targets (confidence score ≥ 0.9) using the STRING database [72]. Network visualization and analysis were performed with Cytoscape [73]. In the presented data, nodes indicate the herbal constituents, active chemical constituents, targets, or pathways, and edges (or links) indicate their interactions [74]. The degree indicates the number of edges of a node in a network [74].

2.7. Contribution Index Analysis

The contribution of chemical compounds to the pharmacological activity of FDY003 was analyzed using a contribution index (CI) [50] that can be calculated using the following formula:twhere NE indicates the network-based efficacy, n indicates the number of targets of chemical component j, d_i indicates the number of links of target i of chemical component j, m indicates the number of chemical components, and c_i (or c_j) indicates the number of previous literatures containing the terms “breast cancer” and the common name of chemical component i (or j) in their title or abstract that were retrieved from the PubMed (https://pubmed.ncbi.nlm.nih.gov/). If the sum of the highest CIs is greater than 85%, the compounds with those CIs are considered the major contributors, as previously suggested [50].

2.8. Functional Enrichment Analysis

Gene ontology (GO) enrichment analysis was performed using g:Profiler [75], and pathway enrichment analysis was carried out with Kyoto Encyclopedia of Genes and Genomes (KEGG) databases [76].

3. Results

3.1. Anticancer Properties of FDY003 against Breast Cancer

To investigate whether FDY003 exerts therapeutic effects on BC cells, we treated MCF-7 (an estrogen receptor-positive human BC cell line), MDA-MB-453 (a human epidermal growth factor receptor 2- (HER2-) positive human BC cell line), and MDA-MB-231 (a triple-negative human BC cell line) cells with FDY003 for 72 h and observed their responses. We found that FDY003 repressed the viability of MCF-7 (IC₅₀ = 242.90 μg/mL), MDA-MB-453 (IC₅₀ = 156.01 μg/mL), and MDA-MB-231 (IC₅₀ = 197.56 μg/mL) cells (Supplementary Figure S1), suggesting that the herbal medicine possesses anti-BC properties.

3.2. Chemical Components of FDY003

The chemical compounds that are present in FDY003 were obtained from the comprehensive databases associated with herbal medicine such as TCMSP and CancerHSP [40, 41]. Accordingly, 323 compounds were retrieved for FDY003 after removing duplicates (Supplementary Table S1).

3.3. Active Chemical Compounds in FDY003

Compounds whose pharmacokinetic parameters met the following criteria were considered active as described in Section 2.4: OB ≥ 30%, Caco-2 permeability ≥ −0.4, and DL ≥ 0.18 [49, 50]. A number of compounds not satisfying the aforementioned criteria were also considered bioactive because they were present in large amounts in herbal medicines and were known to have potent pharmacological efficacy. As a result, we obtained 20 active compounds for FDY003 (Supplementary Table S2).

3.4. Targets of Active Chemical Compounds in FDY003

We used comprehensive chemical-protein interaction data obtained from various relevant databases, including STITCH [51], SEA [55], SwissTargetPrediction [52, 53], and PharmMapper [54] to explore the molecular targets for the bioactive chemical components in FDY003. In addition, in silico models, such as SysDT [56] and WES algorithms [57], were used for the target exploration based on previously described procedures [58–63]. Consequently, we obtained 196 targets for the 18 active compounds (i.e., 4′-methylcapillarisin, arcapillin, artepillin A, capillarisin, chrysoeriol, cirsimaritin, cordycepin, corymbosin, eriodyctiol (flavanone), eupalitin, eupatolitin, genkwanin, isoarcapillin, isorhamnetin, kaempferol, luteolin, quercetin, and β-sitosterol) in FDY003 (Figure 1 and Supplementary Table S3). No interacting targets were retrieved for the compounds “loniceracetalides B_qt” and “demethoxycapillarisin.”

3.5. Network Pharmacology Study on the Molecular Mechanisms of FDY003

To conduct network pharmacology analysis of the molecular mechanisms of FDY003 against BC, we first generated an herbal medicine-bioactive compound-target (H-C-T) network of the herbal formula by linking the herbal medicines with their bioactive chemical components and the components with the targets (Figure 2). The resulting H-C-T network contained 217 nodes (3 herbal medicines, 18 active chemical components, and 196 targets) and 354 edges (Figure 2). In addition, to obtain insight into the BC-associated pharmacological features of FDY003, we constructed a C-T network (158 nodes with 254 edges) by connecting the bioactive chemical components with the BC-associated targets (Figure 3 and Supplementary Table S3). The quercetin, luteolin, kaempferol, cordycepin, eriodyctiol (flavanone), isorhamnetin, and β-sitosterol exhibited the highest degrees (Figure 3 and Supplementary Table S3), implying that they are essential for the mediation of the anticancer effects of FDY003 against BC. Furthermore, 42 BC-associated targets interacted with two or more compounds (Figure 3 and Supplementary Table S3), supporting the polypharmacological characteristics of FDY003.

To investigate the interactive associations among the targets, we built a PPI network (106 nodes and 315 edges) consisting of the BC-associated therapeutic targets of FDY003 (Figure 4). Subsequently, we explored the existence of hubs (i.e., nodes with relatively high degrees that tend to play prominent roles in the cellular processes in a network) [77, 78]. In the analysis, we defined hubs as nodes with degrees equal to or greater than twice the mean node degree [79, 80]. Among the BC-associated targets of FDY003, TP53, SRC, PIK3R1, VEGFA, AKT1, EGFR, CYP1A1, CYP3A4, JUN, CDK1, and ESR1 were hub nodes (Figure 4), suggesting that the nodes act as important targets mediating the therapeutic effects of FDY003 against BC cells. Loss of function of p53 (encoded by TP53) due to genetic alterations has been shown to drive the tumorigenesis, progression, and metastasis of BC; p53 expression has been reported to be a potential prognostic indicator for BC patients [81–89]. The dysregulation and elevated activity of the kinase Src (encoded by SRC) is frequently observed in multiple human malignancies, including BC, and it promotes the invasion, metastasis, migration, and proliferation of BC cells [90–94]. The expression and activity of SRC or PIK3R1 are highly upregulated in malignant breast tumor tissues and have been correlated with decreased survival of BC patients [95–97]. VEGF-A (encoded by VEGFA) is a crucial regulator in the proliferation, angiogenesis, and metastatic behavior of BC cells, and it confers resistance against chemotherapy [98–101]. The overexpression or hyperactivation of AKT (encoded by AKT1), epidermal growth factor receptor (EGFR; encoded by EGFR), or c-Jun (encoded by JUN) promotes various cancerous processes, including proliferation, growth, survival, invasion, and migration of BC cells and is further related to the poorer clinical outcomes of BC patients [102–127]. Such targets have been implicated in reduced drug sensitivity of cancer cells to chemotherapeutics; therefore, targeting them could improve the therapeutic efficacy of chemotherapy and radiotherapy in BC [104–106, 109, 111–113, 117, 119, 123, 125, 126, 128–131]. Cytochrome P450 1A1 (encoded by CYP1A1) and cytochrome P450 3A4 (encoded by CYP3A4) are modulators of estrogen metabolism, and their activities are involved in the cancerous processes of BC cells [132–139]. Genetic polymorphism and expression of CYP3A1 or CYP3A4 in breast tumor tissues have been reported to be potentially useful factors for the prediction of treatment responses to chemotherapy [140, 141]. CDK1 (encoded by CDK1) functions as a crucial regulator in cell cycle progression, and its dysregulation leads to aberrant proliferation of BC cells [142]. Previous studies have indicated that CDK1 activity may act as a prognostic indicator in BC, and CDK1 targeting can increase chemotherapeutic efficacy [143–147]. Abnormal activity of estrogen receptor α (encoded by ESR1) is considered primarily responsible for tumorigenesis and progression of BC, and the receptor is the most promising therapeutic target [134–139].

To assess the contribution of the chemical components to the pharmacological effects of FDY003, we calculated CIs for the individual active compounds (Section 2.7) [50, 148]. As a result, quercetin and luteolin had the highest CIs with a sum of 91.83% (Supplementary Figure S2), which suggests that the two active components are key factors contributing to the FDY003 anticancer properties in BC treatment.

Overall, the results of the analyses above facilitate the identification of the polypharmacological mechanisms of FDY003 activity against BC.

3.6. Functional Enrichment Analysis for the FDY003 Network

To investigate the biological roles of the BC-related targets of FDY003, we carried out GO enrichment analysis for the targets. These targets were enriched in GO terms for the modulation of biological processes, involving cell proliferation, cell cycle progression, and cell apoptosis (Supplementary Figure S3), highlighting the molecular properties of FDY003 activity.

The aberrant activities of oncogenic cellular signalings are known to be responsible for cancer development and progression [149]. To this end, we next carried out pathway enrichment analysis for its BC-related targets (Figure 5 and Supplementary Figure S3). We found that the following diverse pathways, which importantly function in the tumorigenesis and progression of BC, were significantly enriched with the FDY003 targets: “Pathways in cancer,” “PI3K-Akt signaling pathway,” “Endocrine resistance,” “MAPK signaling pathway,” “Focal adhesion,” “Cellular senescence,” “FoxO signaling pathway,” “TNF signaling pathway,” “EGFR tyrosine kinase inhibitor resistance,” “Estrogen signaling pathway,” “Ras signaling pathway,” “Steroid hormone biosynthesis,” “Apoptosis,” “Breast cancer,” “HIF-1 signaling pathway,” “PD-L1 expression and PD-1 checkpoint pathway in cancer,” “Cell cycle,” “ErbB signaling pathway,” “Wnt signaling pathway,” “p53 signaling pathway,” “VEGF signaling pathway,” and “Platinum drug resistance” (Figure 5 and Supplementary Figure S3). The dysregulation of PI3K-Akt, MAPK, focal adhesion, and Ras signaling pathways promotes diverse cancerous cell processes, including the uncontrolled cell proliferation, invasion, migration, survival, metastasis, and angiogenesis of BC cells [3, 126, 150–154]. Abnormalities of crucial cellular function, such as senescence, apoptosis, and cell cycle, are the important pathological processes of BC [155–160]. The TNF signaling pathway is a mediator of the inflammatory process, and its activity is closely linked with the progression, metastasis, and poor prognosis of BC [161, 162]. The estrogen signaling pathway functions as the most critical regulator of tumor initiation and malignant progression in BC, and therapeutic modulation of its activity serves as a primary treatment strategy [163–167]. Previous studies have suggested that expression of programmed death-ligand 1 (PD-L1) serves as a prognostic factor for the survival of patients with BC and that inhibition of the programmed cell death protein 1 (PD-1)/PD-L1 pathway can enhance antitumor responses [168–172]. The HIF-1 and Wnt signaling regulate various cellular behaviors, involving cell proliferation, metastasis, and stem cell-like characteristics in BC cells [173–180]. The p53 signaling pathway exerts tumor-suppressive activity associated with cell cycle arrest, apoptosis, and cellular senescence, and loss of function of its key pathway components has been implicated in the carcinogenesis of BC and is a negative prognostic factor for patient survival [85, 181]. The VEGF signaling pathway plays a protumoral role by increasing angiogenesis, thus promoting the survival, migration, and invasion of BC cells [101, 182]. In addition, resistance to platinum-based drugs, endocrine therapy, and EGFR signaling inhibitors are major obstacles in BC treatment [183–189].

We further analyzed the functional associations among FDY003 targets using GeneMANIA [190], an algorithm useful for the analysis of biological functions of cellular components based on extensive network integration. Among the BC-associated targets of FDY003, 38.32% and 33.65% of them tended to be coexpressed and physically interacting, respectively (Supplementary Figure S4), suggesting that they have similar biological roles and functions.

Together, the results above suggest that FDY003 exerts the pharmacological activity by targeting diverse BC-associated oncogenic signaling pathways and the modulation of relevant biological functions.

4. Discussion

BC is a common cancer type and ranks as the leading cause of death among women globally [1]. Herbal medicines are attracting considerable attention for potential applications in cancer treatment owing to their high anticancer activities, reduced toxicity, and minimal adverse effects [21]. Based on a network pharmacology analysis, we explored the molecular mechanisms of the therapeutic effects of FDY003 for BC. (i) FDY003 exhibited anticancer effects on human BC cells (Supplementary Figure 1). (ii) Eighteen potentially active compounds (i.e., 4′-methylcapillarisin, arcapillin, artepillin A, capillarisin, chrysoeriol, cirsimaritin, cordycepin, corymbosin, eriodyctiol (flavanone), eupalitin, eupatolitin, genkwanin, isoarcapillin, isorhamnetin, kaempferol, luteolin, quercetin, and β-sitosterol) present in FDY003 may interact with 140 BC-associated therapeutic targets and induce the pharmacological activity of the herbal drug (Figures 1–4). (iii) GO terms for the modulation of cellular processes were significantly enriched for the FDY003 targets, including cell proliferation, cell cycle process, and cell apoptosis (Supplementary Figure 3). In addition, (iv) diverse pathways that play key roles in BC pathology were enriched for the targets that included PI3K-Akt, MAPK, focal adhesion, FoxO, TNF, and estrogen signaling pathways (Figure 5 and Supplementary Figure 3).

The FDY003 constituents have been reported to exert inhibitory effects against BC. AcT inhibited the proliferation but induced the death of BC cells [191]. Cm has been previously demonstrated to reduce the migratory and proliferative capacities of BC cells and to stimulate apoptosis by promoting caspase activation and Akt inactivation [29, 35, 192, 193]. Cm also has immunomodulatory properties that can inhibit the growth of breast tumors [194]. Capillarisin exhibits its anticancer effects by attenuating the invasive and proliferative properties of BC cells [195]. Chrysoeriol treatment has been reported to promote apoptosis and cell cycle arrest and further repress the invasion, proliferation, and migration of BC cells [196, 197]. Cirsimaritin inhibits proliferation and angiogenesis via the downregulation of VEGF, Akt, and extracellular signal-regulated kinase (ERK) [198]. Cordycepin is a potent inhibitor of the invasion and proliferation of BC cells while inducing their apoptosis through the regulation of MAPK and caspase-dependent pathways [199–203]. Cordycepin has also been shown to function as a radiosensitizer that can enhance the efficacy of radiotherapy toward BC cells [204]. Genkwanin modulates the activities of CYP1 enzymes and PI3K/Akt/mammalian target of rapamycin (mTOR) pathways, thereby suppressing proliferation and inducing apoptosis of BC cells [205–207]. Isorhamnetin exerts the anticancer activity against BC cells by inhibiting their proliferative and invasive abilities [208–210]. β-Sitosterol activates key apoptotic pathways, including Fas and caspase signaling pathways, and reduces the viability of BC cells [211–214]. Furthermore, β-sitosterol has been demonstrated to elevate the pharmacological effectiveness of tamoxifen, a selective estrogen receptor modulator that is extensively applied in clinical practice [215]. Kaempferol, luteolin, and quercetin stimulate apoptotic cell death but inhibit cell processes, including proliferation, cell cycle progression, angiogenesis, migration, invasion, metastasis, and cancer stemness; such effects occur via the regulation of important BC-associated pathways such as the Akt, caspase, EGFR, estrogen, HER2, MAPK, insulin-like growth factor (IGF)-1, Notch, and Wnt signaling pathways [216–266]. The three chemical compounds have also been shown to sensitize BC cells to various anticancer drugs, including cisplatin, docetaxel, doxorubicin, lapatinib, paclitaxel, rapamycin, sorafenib, tamoxifen, topotecan, and vincristine [267–286]. For instance, luteolin can synergistically enhance the growth-suppression and apoptosis-inducing activities of the anticancer agent celecoxib against BC cells by blocking the activation of oncogenic Akt and ERK signaling [271, 272]. The combined treatment of quercetin with kaempferol or luteolin has synergistic antiproliferative effects that are greater than those of either treatment exclusively [287, 288]. The risk of BC incidence showed a tendency to be lower in women with higher quercetin intakes [289].

Pharmacologic effects of FDY003 in cancer cells have been previously reported [24, 25]. FDY003 has been reported to exert its anticancer effects through the regulation of the activities of key mediators of apoptosis and cell cycle progression; these involved Bax, caspase-3, p21, and p53 that induce apoptosis while suppressing the proliferative and survival capacities of cancer cells [24, 25]. Treatment with the herbal formula further inhibited tumor growth in xenograft mice bearing human cancer cells [24], suggesting in vivo therapeutic effects against cancer. Contrary to the treatment with irinotecan, a clinically used cytotoxic chemotherapeutic agent [290], body weight loss (a parameter used to evaluate the potential toxicity of drug treatments in animal experiments) did not occur in FDY003-administered xenograft mice [24], suggesting tolerability of the herbal drug as well as its antitumor activity. Future experimental studies should (i) investigate the pharmacological effects of FDY003 in diverse types of cancer, (ii) explore the mechanisms underlying the anticancer activity of the herbal formula such as its immunomodulatory effects, and (iii) evaluate the anticancer effectiveness and safety of FDY003 combined with other widely used therapeutic approaches (i.e., chemotherapy, endocrine therapy, and targeted molecular therapy). Such studies would facilitate the development of safer and more effective herbal medicine-based strategies for BC treatment.

5. Conclusions

We explored the systematic mechanisms of FDY003 activity against BC based on a network pharmacology analysis. FDY003 elicited anticancer effects on human BC cells. Eighteen chemical compounds in FDY003 were identified as potentially bioactive compounds that could target 140 BC-associated genes/proteins and exhibit therapeutic effects. The FDY003 targets were enriched in GO terms associated with the modulation of cellular processes, involving cell proliferation, cell cycle progression, and cell apoptosis. Pathway enrichment analysis of the targets further demonstrated that diverse pathways crucial for the BC pathology were significantly enriched with the FDY003 targets, involving the PI3K-Akt, MAPK, focal adhesion, FoxO, TNF, and estrogen signaling pathways. Based on a network perspective, our findings offer in-depth insights into the therapeutic properties of herbal medicines in BC treatment. Future studies should explore the potential efficacy of the herbal formula in other cancer types as well as its potential efficacy and safety profiles in combination with other therapies.

Abbreviations

AcT:	Artemisia capillaris Thunberg
ADME:	Absorption, distribution, metabolism, and excretion
Bax:	Bcl-2-associated X protein
C-T:	Compound-target
CI:	Contribution index
Cm:	Cordyceps militaris
CTD:	The Comparative Toxicogenomics Database
CYP:	Cytochrome P450
DL:	Drug-likeness
EGFR:	Epidermal growth factor receptor
ErbB:	Erythroblastic leukemia viral oncogene homolog
FoxO:	Forkhead box protein O
GO:	Gene ontology
H-C:	Herb-compound
H-C-T:	Herb-target-pathway
HIF-1:	Hypoxia-inducible factor 1
HuGE Navigator:	Human Genome Epidemiology Navigator
KEGG:	Kyoto Encyclopedia of Genes and Genomes
LjT:	Lonicera japonica Thunberg
MAPK:	Mitogen-activated protein kinase
MTT:	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NE:	Network-based efficacy
OB:	Oral bioavailability
OMIM:	Online Mendelian Inheritance in Man
PD-1:	Programmed cell death protein 1
PD-L1:	Programmed death-ligand 1
PharmGKB:	Pharmacogenomics Knowledgebase
PI3K:	Phosphoinositide 3-kinase
PPI:	Protein-protein interaction
QOL:	Quality of life
SEA:	Similarity ensemble approach
STITCH:	Search Tool for Interactions of Chemicals
SysDT:	Systematic drug targeting tool
TCMSP:	Traditional Chinese medicine systems pharmacology
TTD:	Therapeutic Target Database
TNF:	Tumor necrosis factor
T-P:	Target-pathway
VEGF:	Vascular endothelial growth factor
WES algorithm:	Weighted ensemble similarity algorithm.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

This study was funded by the Fore and Forest Hospital.

Supplementary Materials

Supplementary Figure S1. Effects of FDY003 on the viability of breast cancer cells. Supplementary Figure S2. Contribution index of active compounds in FDY003. Supplementary Figure S3. Functional enrichment analysis for the breast cancer-associated targets of FDY003. Supplementary Figure S4. Functional interaction analysis for the breast cancer-associated targets of FDY003. Supplementary Table S1. List of the chemical compounds in FDY003. Supplementary Table S2. List of the active chemical compounds in FDY003. Supplementary Table S3. List of the targets of active chemical compounds in FDY003. (Supplementary Materials)

References

C. E. DeSantis, J. Ma, M. M. Gaudet et al., “Breast cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 6, pp. 438–451, 2019.
View at: Publisher Site | Google Scholar
R. Garcia-Becerra, N. Santos, L. Diaz, and J. Camacho, “Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance,” International Journal of Molecular Sciences, vol. 14, no. 1, pp. 108–145, 2020.
View at: Google Scholar
P. F. McAuliffe, F. Meric-Bernstam, G. B. Mills, and A. M. Gonzalez-Angulo, “Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis,” Clinical Breast Cancer, vol. 10, no. 3, pp. S59–S65, 2010.
View at: Publisher Site | Google Scholar
D. Zardavas, J. Baselga, and M. Piccart, “Emerging targeted agents in metastatic breast cancer,” Nature Reviews Clinical Oncology, vol. 10, no. 4, pp. 191–210, 2013.
View at: Google Scholar
P. den Hollander, M. I. Savage, and P. H. Brown, “Targeted therapy for breast cancer prevention,” Frontiers in Oncology, vol. 3, p. 250, 2013.
View at: Google Scholar
X. Li, M. T. Lewis, J. Huang et al., “Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy,” Journal of the National Cancer Institute, vol. 100, no. 9, pp. 672–679, 2008.
View at: Google Scholar
R. Nahta, D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva, “Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer,” Nature Clinical Practice Oncology, vol. 3, no. 5, pp. 269–280, 2006.
View at: Google Scholar
M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005.
View at: Google Scholar
E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1673–1684, 2005.
View at: Google Scholar
R. Rouzier, C. M. Perou, W. F. Symmans et al., “Breast cancer molecular subtypes respond differently to preoperative chemotherapy,” Clinical Cancer Research, vol. 11, no. 16, pp. 5678–5685, 2005.
View at: Google Scholar
M. Abotaleb, P. Kubatka, M. Caprnda et al., “Chemotherapeutic agents for the treatment of metastatic breast cancer: an update,” Biomedicine & Pharmacotherapy, vol. 101, pp. 458–477, 2018.
View at: Google Scholar
S. Ali, M. Rasool, H. Chaoudhry et al., “Molecular mechanisms and mode of tamoxifen resistance in breast cancer,” Bioinformation, vol. 12, no. 3, pp. 135–139, 2016.
View at: Google Scholar
E. A. Ariazi, J. L. Ariazi, F. Cordera, and V. C. Jordan, “Estrogen receptors as therapeutic targets in breast cancer,” Current Topics in Medicinal Chemistry, vol. 6, no. 3, pp. 181–202, 2006.
View at: Google Scholar
A. Farolfi, E. Melegari, M. Aquilina et al., “Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors,” Heart, vol. 99, no. 9, pp. 634–639, 2013.
View at: Google Scholar
M. Fiuza, “Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer,” Advances in Therapy, vol. 26, no. 1, pp. S9–S17, 2009.
View at: Google Scholar
E. L. Mayer and H. J. Burstein, “Chemotherapy for metastatic breast cancer,” Hematology/Oncology Clinics of North America, vol. 21, no. 2, pp. 257–272, 2007.
View at: Google Scholar
A. H. Partridge, H. J. Burstein, and E. P. Winer, “Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer,” JNCI: Journal of the National Cancer Institute, vol. 30, pp. 135–142, 2001.
View at: Google Scholar
B. Ramaswamy and C. L. Shapiro, “Osteopenia and osteoporosis in women with breast cancer,” Seminars in Oncology, vol. 30, no. 6, pp. 763–775, 2003.
View at: Google Scholar
G. R. Zimmermann, J. Lehar, and C. T. Keith, “Multi-target therapeutics: when the whole is greater than the sum of the parts,” Drug Discovery Today, vol. 12, no. 1-2, pp. 34–42, 2007.
View at: Google Scholar
S. Ohnishi and H. Takeda, “Herbal medicines for the treatment of cancer chemotherapy-induced side effects,” Frontiers in Pharmacology, vol. 6, p. 14, 2015.
View at: Google Scholar
P. Poornima, J. D. Kumar, Q. Zhao, M. Blunder, and T. Efferth, “Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature,” Pharmacological Research, vol. 111, pp. 290–302, 2016.
View at: Google Scholar
S. Y. Yin, W. C. Wei, F. Y. Jian, and N. S. Yang, “Therapeutic applications of herbal medicines for cancer patients,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 302426, 15 pages, 2013.
View at: Publisher Site | Google Scholar
L. Zhu, L. Li, Y. Li, J. Wang, and Q. Wang, “Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 9469276, 17 pages, 2016.
View at: Publisher Site | Google Scholar
I.-H. Lee and D.-Y. Lee, “FDY003 inhibits colon cancer in a Colo205 xenograft mouse model by decreasing oxidative stress,” Pharmacognosy Magazine, vol. 15, no. 65, p. 675, 2019.
View at: Google Scholar
H.-S. Lee, I.-H. Lee, K. Kang et al., “Systems pharmacology study of the anticervical cancer mechanisms of FDY003,” Natural Product Communications, vol. 15, no. 12, 2020.
View at: Google Scholar
G. Feng, X. Wang, C. You et al., “Antiproliferative potential of Artemisia capillaris polysaccharide against human nasopharyngeal carcinoma cells,” Carbohydrate Polymers, vol. 92, no. 2, pp. 1040–1045, 2013.
View at: Google Scholar
M. Hokin-Neaverson and J. W. Jefferson, “Deficient erythrocyte NaK-ATPase activity in different affective states in bipolar affective disorder and normalization by lithium therapy,” Neuropsychobiology, vol. 22, no. 1, pp. 18–25, 1989.
View at: Google Scholar
E. Jang, S. Y. Kim, N. R. Lee et al., “Evaluation of antitumor activity of Artemisia capillaris extract against hepatocellular carcinoma through the inhibition of IL-6/STAT3 signaling axis,” Oncology Reports, vol. 37, no. 1, pp. 526–532, 2017.
View at: Google Scholar
C. Y. Jin, G. Y. Kim, and Y. H. Choi, “Induction of apoptosis by aqueous extract of Cordyceps militaris through activation of caspases and inactivation of Akt in human breast cancer MDA-MB-231 Cells,” Journal of Microbiology and Biotechnology, vol. 18, no. 12, pp. 1997–2003, 2008.
View at: Google Scholar
J. Kim, K. H. Jung, H. H. Yan et al., “Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma,” BMC Complementary Medicine and Therapies, vol. 18, no. 1, p. 147.
View at: Google Scholar
K. I. Park, H. Park, A. Nagappan et al., “Polyphenolic compounds from Korean Lonicera japonica Thunb. induces apoptosis via AKT and caspase cascade activation in A549 cells,” Oncology Letters, vol. 13, no. 4, pp. 2521–2530, 2017.
View at: Google Scholar
Y. K. Rao, S. H. Fang, W. S. Wu, and Y. M. Tzeng, “Constituents isolated from Cordyceps militaris suppress enhanced inflammatory mediator's production and human cancer cell proliferation,” Journal of Ethnopharmacology, vol. 131, no. 2, pp. 363–367, 2010.
View at: Google Scholar
H. S. Yoo, J. W. Shin, J. H. Cho et al., “Effects of Cordyceps militaris extract on angiogenesis and tumor growth,” Acta Pharmacologica Sinica, vol. 25, no. 5, pp. 657–665, 2004.
View at: Google Scholar
Q. Zhou, Z. Zhang, L. Song et al., “Cordyceps militaris fraction inhibits the invasion and metastasis of lung cancer cells through the protein kinase B/glycogen synthase kinase 3beta/beta-catenin signaling pathway,” Oncology Letters, vol. 16, no. 6, pp. 6930–6939, 2018.
View at: Google Scholar
C. Chen, M.-L. Wang, C. Jin et al., “Cordyceps militaris polysaccharide triggers apoptosis and G0/G1 cell arrest in cancer cells,” Journal of Asia-Pacific Entomology, vol. 18, no. 3, pp. 433–438, 2015.
View at: Google Scholar
C. Hao da and P. G. Xiao, “Network pharmacology: a Rosetta Stone for traditional Chinese medicine,” Drug Discovery Today, vol. 75, no. 5, pp. 299–312, 2014.
View at: Google Scholar
H. S. Lee, I. H. Lee, S. I. Park, and D. Y. Lee, “Network pharmacology-based investigation of the system-level molecular mechanisms of the hematopoietic activity of samul-tang, a traditional Korean herbal formula,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 9048089, 2020.
View at: Publisher Site | Google Scholar
W. Y. Lee, C. Y. Lee, Y. S. Kim, and C. E. Kim, “The methodological trends of traditional herbal medicine employing network pharmacology,” Biomolecules, vol. 9, 8 pages, 2019.
View at: Google Scholar
G. B. Zhang, Q. Y. Li, Q. L. Chen, and S. B. Su, “Network pharmacology: a new approach for Chinese herbal medicine research,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 621423, 9 pages, 2013.
View at: Publisher Site | Google Scholar
J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” Journal of Cheminformatics, vol. 6, p. 13, 2014.
View at: Google Scholar
W. Tao, B. Li, S. Gao et al., “CancerHSP: anticancer herbs database of systems pharmacology,” Scientific Reports, vol. 5, p. 11481, 2015.
View at: Google Scholar
C. K. Wang and D. J. Craik, “Cyclic peptide oral bioavailability: lessons from the past,” Biopolymers, vol. 106, no. 6, pp. 901–909, 2016.
View at: Google Scholar
M. N. Garcia, C. Flowers, and J. D. Cook, “The Caco-2 cell culture system can be used as a model to study food iron availability,” Journal of Nutrition, vol. 126, no. 1, pp. 251–258, 1996.
View at: Google Scholar
Y. Kono, A. Iwasaki, K. Matsuoka, and T. Fujita, “Effect of mechanical agitation on cationic liposome transport across an unstirred water layer in caco-2 cells,” Biological and Pharmaceutical Bulletin, vol. 39, no. 8, pp. 1293–1299, 2016.
View at: Google Scholar
D. A. Volpe, “Variability in Caco-2 and MDCK cell-based intestinal permeability assays,” Journal of Pharmaceutical Sciences, vol. 97, no. 2, pp. 712–725, 2008.
View at: Google Scholar
Y. Li, J. Zhang, L. Zhang et al., “Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula,” Journal of Ethnopharmacology, vol. 174, pp. 45–56, 2015.
View at: Google Scholar
J. Zhang, Y. Li, X. Chen, Y. Pan, S. Zhang, and Y. Wang, “Systems pharmacology dissection of multi-scale mechanisms of action for herbal medicines in stroke treatment and prevention,” PLoS One, vol. 9, no. 8, Article ID e102506, 2014.
View at: Google Scholar
A. Y. Lee, W. Park, T. W. Kang, M. H. Cha, and J. M. Chun, “Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis,” Journal of Ethnopharmacology, vol. 221, pp. 151–159, 2018.
View at: Google Scholar
J. Huang, F. Cheung, H. Y. Tan et al., “Identification of the active compounds and significant pathways of yinchenhao decoction based on network pharmacology,” Molecular Medicine Reports, vol. 16, no. 4, pp. 4583–4592, 2017.
View at: Google Scholar
S. J. Yue, L. T. Xin, Y. C. Fan et al., “Herb pair Danggui-Honghua: mechanisms underlying blood stasis syndrome by system pharmacology approach,” Scientific Reports, vol. 7, p. 40318, 2017.
View at: Google Scholar
D. Szklarczyk, A. Santos, C. von Mering, L. J. Jensen, P. Bork, and M. Kuhn, “STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data,” Nucleic Acids Research, vol. 44, no. D1, pp. D380–D384, 2015.
View at: Google Scholar
A. Daina, O. Michielin, and V. Zoete, “SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules,” Nucleic Acids Research, vol. 47, no. W1, pp. W357–W364, 2019.
View at: Google Scholar
D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin, and V. Zoete, “SwissTargetPrediction: a web server for target prediction of bioactive small molecules,” Nucleic Acids Research, vol. 42, pp. W32–W38, 2014.
View at: Google Scholar
X. Wang, Y. Shen, S. Wang et al., “PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database,” Nucleic Acids Research, vol. 45, no. W1, pp. W356–W360, 2017.
View at: Google Scholar
M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, “Relating protein pharmacology by ligand chemistry,” Nat Biotechnol, vol. 25, no. 2, pp. 197–206, 2007.
View at: Google Scholar
H. Yu, J. Chen, X. Xu et al., “A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data,” PLoS One, vol. 7, no. 5, Article ID e37608, 2012.
View at: Google Scholar
C. Zheng, Z. Guo, C. Huang et al., “Large-scale direct targeting for drug repositioning and discovery,” Scientific Reports, vol. 5, p. 11970, 2015.
View at: Google Scholar
J. Liu, M. Jiang, Z. Li et al., “A novel systems pharmacology method to investigate molecular mechanisms of scutellaria barbata D. Don for non-small cell lung cancer,” Frontiers in Pharmacology, vol. 9, p. 1473, 2018.
View at: Google Scholar
X. Su, Y. Li, M. Jiang et al., “Systems pharmacology uncover the mechanism of anti-non-small cell lung cancer for Hedyotis diffusa Willd,” Biomedicine & Pharmacotherapy, vol. 109, pp. 969–984, 2019.
View at: Google Scholar
J. Wang, L. Zhang, B. Liu et al., “Systematic investigation of the Erigeron breviscapus mechanism for treating cerebrovascular disease,” Journal of Ethnopharmacology, vol. 224, pp. 429–440, 2018.
View at: Google Scholar
J. Liu, J. Liu, F. Shen et al., “Systems pharmacology analysis of synergy of TCM: an example using saffron formula,” Scientific Reports, vol. 8, no. 1, p. 380, 2018.
View at: Google Scholar
J. Liu, J. Zhu, J. Xue et al., “In silico-based screen synergistic drug combinations from herb medicines: a case using Cistanche tubulosa,” Scientific Reports, vol. 7, no. 1, p. 16364, 2017.
View at: Google Scholar
J. Liu, T. Pei, J. Mu et al., “Systems pharmacology uncovers the multiple mechanisms of xijiao dihuang decoction for the treatment of viral hemorrhagic fever,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 9025036, 17 pages, 2016.
View at: Publisher Site | Google Scholar
F. Zhu, B. Han, P. Kumar et al., “Update of TTD: therapeutic target database,” Nucleic Acids Research, vol. 38, pp. D787–D791, 2009.
View at: Google Scholar
M. Safran, I. Dalah, J. Alexander et al., “GeneCards Version 3: the human gene integrator,” Database, vol. 2010, p. baq020, 2010.
View at: Publisher Site | Google Scholar
A. P. Davis, C. J. Grondin, R. J. Johnson et al., “The comparative Toxicogenomics database: update 2019,” Nucleic Acids Research, vol. 47, no. D1, pp. D948–D954, 2019.
View at: Google Scholar
J. Pinero, A. Bravo, N. Queralt-Rosinach et al., “DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants,” Nucleic Acids Research, vol. 45, no. D1, pp. D833–D839, 2017.
View at: Google Scholar
W. Yu, M. Gwinn, M. Clyne, A. Yesupriya, and M. J. Khoury, “A navigator for human genome epidemiology,” Nature Genetics, vol. 40, no. 2, pp. 124-125, 2008.
View at: Google Scholar
J. S. Amberger, C. A. Bocchini, F. Schiettecatte, A. F. Scott, and A. Hamosh, “OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders,” Nucleic Acids Research, vol. 43, pp. D789–D798, 2015.
View at: Google Scholar
M. Whirl-Carrillo, E. M. McDonagh, J. M. Hebert et al., “Pharmacogenomics knowledge for personalized medicine,” Clin Pharmacol Ther, vol. 92, no. 4, pp. 414–417, 2012.
View at: Google Scholar
D. S. Wishart, Y. D. Feunang, A. C. Guo et al., “DrugBank 5.0: a major update to the DrugBank database for 2018,” Nucleic Acids Research, vol. 46, no. D1, pp. D1074–D1082, 2017.
View at: Google Scholar
D. Szklarczyk, A. L. Gable, D. Lyon et al., “STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets,” Nucleic Acids Research, vol. 47, no. D1, pp. D607–D613, 2019.
View at: Google Scholar
P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
View at: Google Scholar
A. L. Barabasi and Z. N. Oltvai, “Network biology: understanding the cell's functional organization,” Nature Reviews Genetics, vol. 5, no. 2, pp. 101–113, 2004.
View at: Google Scholar
U. Raudvere, L. Kolberg, I. Kuzmin et al., “g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update),” Nucleic Acids Research, W1, vol. 47, pp. W191–W198, 2019.
View at: Google Scholar
M. Kanehisa and S. Goto, “KEGG: kyoto encyclopedia of genes and genomes,” Nucleic Acids Research, vol. 28, no. 1, pp. 27–30, 2000.
View at: Google Scholar
D. Y. Cho, Y. A. Kim, and T. M. Przytycka, “Chapter 5: network biology approach to complex diseases,” PLoS Computational Biology, vol. 8, no. 12, Article ID e1002820, 2012.
View at: Google Scholar
H. Jeong, S. P. Mason, A. L. Barabasi, and Z. N. Oltvai, “Lethality and centrality in protein networks,” Nature, vol. 411, no. 6833, pp. 41-42, 2001.
View at: Google Scholar
J. Zhu, X. Yi, Y. Zhang, Z. Pan, L. Zhong, and P. Huang, “Systems pharmacology-based approach to comparatively study the independent and synergistic mechanisms of danhong injection and naoxintong capsule in ischemic stroke treatment,” Evidence-Based Complementary and Alternative Medicine, vol. 2019, Article ID 1056708, 17 pages, 2010.
View at: Publisher Site | Google Scholar
J. Zhong, Z. Liu, X. Zhou, and J. Xu, “Synergic anti-pruritus mechanisms of action for the radix sophorae flavescentis and fructus cnidii herbal pair,” Molecules, vol. 22, 9 pages, 2017.
View at: Google Scholar
L. D. Miller, J. Smeds, J. George et al., “An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13550–13555, 2005.
View at: Google Scholar
P. Yang, C. W. Du, M. Kwan, S. X. Liang, and G. J. Zhang, “The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis,” Scientific Reports, vol. 3, p. 2246, 2020.
View at: Google Scholar
M. D. Wellenstein, S. B. Coffelt, D. E. M. Duits et al., “Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis,” Nature, vol. 572, no. 7770, pp. 538–542, 2019.
View at: Google Scholar
L. Y. Lim, N. Vidnovic, L. W. Ellisen, and C. O. Leong, “Mutant p53 mediates survival of breast cancer cells,” British Journal of Cancer, vol. 101, no. 9, pp. 1606–1612, 2009.
View at: Google Scholar
M. Lacroix, R. A. Toillon, and G. Leclercq, “p53 and breast cancer, an update,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 293–325, 2006.
View at: Google Scholar
H. Yamashita, T. Toyama, M. Nishio et al., “p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer,” Breast Cancer Research, vol. 8, no. 4, p. R48, 2006.
View at: Google Scholar
D. Walerych, M. Napoli, L. Collavin, and G. Del Sal, “The rebel angel: mutant p53 as the driving oncogene in breast cancer,” Carcinogenesis, vol. 33, no. 11, pp. 2007–2017, 2012.
View at: Google Scholar
N. Turner, E. Moretti, O. Siclari et al., “Targeting triple negative breast cancer: is p53 the answer?” Cancer Treatment Reviews, vol. 39, no. 5, pp. 541–550, 2013.
View at: Google Scholar
B. Na, X. Yu, T. Withers et al., “Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation,” NPJ Breast Cancer, vol. 5, p. 14, 2019.
View at: Google Scholar
E. L. Mayer and I. E. Krop, “Advances in targeting SRC in the treatment of breast cancer and other solid malignancies,” Clinical Cancer Research, vol. 16, no. 14, pp. 3526–3532, 2010.
View at: Google Scholar
S. Hiscox, L. Morgan, T. P. Green, D. Barrow, J. Gee, and R. I. Nicholson, “Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells,” Breast Cancer Research and Treatment, vol. 97, no. 3, pp. 263–274, 2006.
View at: Google Scholar
X. H. Zhang, Q. Wang, W. Gerald et al., “Latent bone metastasis in breast cancer tied to Src-dependent survival signals,” Cancer Cell, vol. 16, no. 1, pp. 67–78, 2009.
View at: Google Scholar
F. Saad and A. Lipton, “SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 177–184, 2010.
View at: Google Scholar
H. Jallal, M. L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani, “A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo,” Cancer Research, vol. 67, no. 4, pp. 1580–1588, 2007.
View at: Google Scholar
B. Elsberger, R. Fullerton, S. Zino et al., “Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression,” British Journal of Cancer, vol. 103, no. 6, pp. 899–909, 2010.
View at: Google Scholar
B. S. Verbeek, T. M. Vroom, S. S. Adriaansen-Slot et al., “c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis,” The Journal of Pathology, vol. 180, no. 4, pp. 383–388, 1996.
View at: Google Scholar
Y. Yang, M. Li, and Y. Li, “High expression of PIK3R1 (p85α) correlates with poor survival in patients with metastatic breast cancer,” Int Journal of Clinical and Experimental Pathology, vol. 9, no. 12, pp. 12797–12806.
View at: Google Scholar
H. J. Burstein, Y. H. Chen, L. M. Parker et al., “VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy,” Clinical Cancer Research, vol. 14, no. 23, pp. 7871–7877, 2008.
View at: Google Scholar
Y. Liang, R. A. Brekken, and S. M. Hyder, “Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones,” Endocrine-Related Cancer, vol. 13, no. 3, pp. 905–919, 2006.
View at: Google Scholar
M. Luo, L. Hou, J. Li et al., “VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin,” Cancer Letters, vol. 373, no. 1, pp. 1–11, 2016.
View at: Google Scholar
M. Perrot-Applanat and M. Di Benedetto, “Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion,” Cell Adhesion & Migration, vol. 6, no. 6, pp. 547–553, 2012.
View at: Google Scholar
S. B. Vestey, C. Sen, C. J. Calder, C. M. Perks, M. Pignatelli, and Z. E. Winters, “Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome,” European Journal of Cancer, vol. 41, no. 7, pp. 1017–1025, 2005.
View at: Google Scholar
G. Perez-Tenorio, O. Stal, and G. Southeast Sweden Breast Cancer, “Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients,” British Journal of Cancer, vol. 86, no. 4, pp. 540–545, 2002.
View at: Google Scholar
T. Kirkegaard, C. J. Witton, L. M. McGlynn et al., “AKT activation predicts outcome in breast cancer patients treated with tamoxifen,” The Journal of Pathology, vol. 207, no. 2, pp. 139–146, 2005.
View at: Google Scholar
P. Grell, P. Fabian, M. Khoylou et al., “Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab,” International Journal of Oncology, vol. 41, no. 4, pp. 1204–1212, 2012.
View at: Google Scholar
E. Tokunaga, A. Kataoka, Y. Kimura et al., “The association between Akt activation and resistance to hormone therapy in metastatic breast cancer,” European Journal of Cancer, vol. 42, no. 5, pp. 629–635, 2006.
View at: Google Scholar
M. M. Vleugel, A. E. Greijer, R. Bos, E. van der Wall, and P. J. van Diest, “c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer,” Human Pathology, vol. 37, no. 6, pp. 668–674, 2006.
View at: Google Scholar
X. Jiao, S. Katiyar, N. E. Willmarth et al., “c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion,” Journal of Biological Chemistry, vol. 285, no. 11, pp. 8218–8226, 2010.
View at: Google Scholar
Y. Zhang, X. Pu, M. Shi et al., “c-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy,” Oncology Reports, vol. 18, no. 5, pp. 1207–1212, 2007.
View at: Google Scholar
Y. Zhang, X. Pu, M. Shi et al., “Critical role of c-Jun overexpression in liver metastasis of human breast cancer xenograft model,” BMC Cancer, vol. 7, p. 145, 2007.
View at: Google Scholar
A. E. Teschendorff, L. Li, and Z. Yang, “Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer,” Genome Biology, vol. 16, p. 61, 2015.
View at: Google Scholar
N. M. Davis, M. Sokolosky, K. Stadelman et al., “Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention,” Oncotarget, vol. 5, no. 13, pp. 4603–4650, 2014.
View at: Google Scholar
H. Nogi, T. Kobayashi, M. Suzuki et al., “EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer,” Oncology Reports, vol. 21, no. 2, pp. 413–417, 2009.
View at: Google Scholar
D. Liu, J. He, Z. Yuan et al., “EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray,” Medical Oncology, vol. 29, no. 2, pp. 401–405, 2012.
View at: Google Scholar
S. O. Lim, C. W. Li, W. Xia et al., “EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape,” Cancer Research, vol. 76, no. 5, pp. 1284–1296, 2016.
View at: Google Scholar
K. L. Mueller, K. Powell, J. M. Madden, S. T. Eblen, and J. L. Boerner, “EGFR tyrosine 845 phosphorylation-dependent proliferation and transformation of breast cancer cells require activation of p38 MAPK,” Translational Oncology, vol. 5, no. 5, pp. 327–334, 2012.
View at: Google Scholar
L. Dihge, P. O. Bendahl, D. Grabau et al., “Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer,” Breast Cancer Research and Treatment, vol. 109, no. 2, pp. 255–262, 2008.
View at: Google Scholar
H. S. Park, M. H. Jang, E. J. Kim et al., “High EGFR gene copy number predicts poor outcome in triple-negative breast cancer,” Modern Pathology, vol. 27, no. 9, pp. 1212–1222.
View at: Google Scholar
S. E. Ghayad and P. A. Cohen, “Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients,” Recent Patents on Anti-Cancer Drug Discovery, vol. 5, no. 1, pp. 29–57.
View at: Google Scholar
S. Langer, C. F. Singer, G. Hudelist et al., “Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters,” European Journal of Gynaecological Oncology, vol. 27, no. 4, pp. 345–352, 2014.
View at: Google Scholar
X. L. Yan, C. J. Fu, L. Chen et al., “Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway,” Breast Cancer Research and Treatment, vol. 132, no. 1, pp. 153–164, 2012.
View at: Google Scholar
B. S. Verbeek, S. S. Adriaansen-Slot, T. M. Vroom, T. Beckers, and G. Rijksen, “Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts,” FEBS Letters, vol. 425, no. 1, pp. 145–150, 1998.
View at: Google Scholar
C. A. Castaneda, H. Cortes-Funes, H. L. Gomez, and E. M. Ciruelos, “The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer,” Cancer and Metastasis Reviews, vol. 29, no. 4, pp. 751–759, 2010.
View at: Google Scholar
G. Kallergi, S. Agelaki, A. Kalykaki, C. Stournaras, D. Mavroudis, and V. Georgoulias, “Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients,” Breast Cancer Research, vol. 10, no. 5, p. R80.
View at: Google Scholar
E. Paplomata and R. O'Regan, “The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers,” Therapeutic Advances in Medical Oncology, vol. 6, no. 4, pp. 154–166, 2008.
View at: Google Scholar
K. S. Saini, S. Loi, E. de Azambuja et al., “Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer,” Cancer Treatment Reviews, vol. 39, no. 8, pp. 935–946, 2013.
View at: Google Scholar
J. Briggs, S. Chamboredon, M. Castellazzi, J. A. Kerry, and T. J. Bos, “Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells,” Oncogene, vol. 21, no. 46, pp. 7077–7091, 2002.
View at: Google Scholar
N. J. Jordan, J. M. Gee, D. Barrow, A. E. Wakeling, and R. I. Nicholson, “Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells,” Breast Cancer Research and Treatment, vol. 87, no. 2, pp. 167–180, 2004.
View at: Google Scholar
J. M. Albert, K. W. Kim, C. Cao, and B. Lu, “Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1183–1189, 2006.
View at: Google Scholar
K. Liang, W. Jin, C. Knuefermann et al., “Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy,” Molecular Cancer Therapeutics, vol. 2, no. 4, pp. 353–360, 2003.
View at: Google Scholar
J. J. Lee, K. Loh, and Y. S. Yap, “PI3K/Akt/mTOR inhibitors in breast cancer,” Cancer Biology & Medicine, vol. 12, no. 4, pp. 342–354, 2015.
View at: Google Scholar
M. Rodriguez and D. A. Potter, “CYP1A1 regulates breast cancer proliferation and survival,” Molecular Cancer Research, vol. 11, no. 7, pp. 780–792, 2013.
View at: Google Scholar
Y. Huang, A. Trentham-Dietz, M. Garcia-Closas et al., “Association of CYP1B1 haplotypes and breast cancer risk in Caucasian women,” Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 4, pp. 1321–1323, 2009.
View at: Google Scholar
C. S. Huang, H. D. Chern, K. J. Chang, C. W. Cheng, S. M. Hsu, and C. Y. Shen, “Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility,” Cancer Research, vol. 59, no. 19, pp. 4870–4875, 1999.
View at: Google Scholar
R. Mitra, Z. Guo, M. Milani et al., “CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (+/-)-14,15-epoxyeicosatrienoic acid (EET),” Journal of Biological Chemistry, vol. 286, no. 20, pp. 17543–17559, 2011.
View at: Google Scholar
N. Napoli, D. T. Villareal, S. Mumm et al., “Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density,” Journal of Bone and Mineral Research, vol. 20, no. 2, pp. 232–239, 2005.
View at: Google Scholar
A. M. Yu, K. Fukamachi, K. W. Krausz, C. Cheung, and F. J. Gonzalez, “Potential role for human cytochrome P450 3A4 in estradiol homeostasis,” Endocrinology, vol. 146, no. 7, pp. 2911–2919, 2005.
View at: Google Scholar
Z. N. Cheng, Y. Shu, Z. Q. Liu, L. S. Wang, D. S. Ou-Yang, and H. H. Zhou, “Role of cytochrome P450 in estradiol metabolism in vitro,” Acta Pharmacologica Sinica, vol. 22, no. 2, pp. 148–154, 2001.
View at: Google Scholar
E. Taioli, H. L. Bradlow, S. V. Garbers et al., “Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk,” Cancer Detection and Prevention, vol. 23, no. 3, pp. 232–237, 1999.
View at: Google Scholar
X. Zhou, G. Qiao, X. Wang et al., “CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine,” Cancer Chemotherapy and Pharmacology, vol. 81, no. 2, pp. 365–372, 2018.
View at: Google Scholar
K. Sakurai, K. Enomoto, S. Matsuo, S. Amano, and M. Shiono, “CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer,” Surgery Today, vol. 41, no. 5, pp. 674–679, 2011.
View at: Google Scholar
S. Izadi, A. Nikkhoo, M. Hojjat-Farsangi et al., “CDK1 in breast cancer: implications for theranostic potential,” Anti-Cancer Agents in Medicinal Chemistry, vol. 20, no. 7, pp. 758–767, 2020.
View at: Google Scholar
Q. Xia, Y. Cai, R. Peng, G. Wu, Y. Shi, and W. Jiang, “The CDK1 inhibitor RO3306 improves the response of BRCA-pro fi cient breast cancer cells to PARP inhibition,” International Journal of Oncology, vol. 44, no. 3, pp. 735–744, 2014.
View at: Google Scholar
S. J. Kim, N. Masuda, F. Tsukamoto et al., “The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy,” Cancer Letters, vol. 355, no. 2, pp. 217–223, 2014.
View at: Google Scholar
S. J. Kim, S. Nakayama, Y. Miyoshi et al., “Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer,” Annals of Oncology, vol. 19, no. 1, pp. 68–72, 2008.
View at: Google Scholar
S. Nakayama, Y. Torikoshi, T. Takahashi et al., “Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells,” Breast Cancer Research, vol. 11, no. 1, p. R12, 2009.
View at: Google Scholar
J. Kang, C. M. Sergio, R. L. Sutherland, and E. A. Musgrove, “Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells,” BMC Cancer, vol. 14, p. 32, 2014.
View at: Google Scholar
S. J. Yue, J. Liu, W. W. Feng et al., “System pharmacology-based dissection of the synergistic mechanism of huangqi and huanglian for diabetes mellitus,” Frontiers in Pharmacology, vol. 8, p. 694, 2017.
View at: Google Scholar
W. Kolch, M. Halasz, M. Granovskaya, and B. N. Kholodenko, “The dynamic control of signal transduction networks in cancer cells,” Nature Reviews Cancer, vol. 15, no. 9, pp. 515–527, 2015.
View at: Google Scholar
K. M. Hardy, B. W. Booth, M. J. Hendrix, D. S. Salomon, and L. Strizzi, “ErbB/EGF signaling and EMT in mammary development and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 15, no. 2, pp. 191–199, 2010.
View at: Google Scholar
M. Luo and J. L. Guan, “Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis,” Cancer Letters, vol. 289, no. 2, pp. 127–139, 2010.
View at: Google Scholar
M. Bullock, “FOXO factors and breast cancer: outfoxing endocrine resistance,” Endocrine-Related Cancer, vol. 23, no. 2, pp. R113–R130, 2016.
View at: Google Scholar
M. Farhan, H. Wang, U. Gaur, P. J. Little, J. Xu, and W. Zheng, “FOXO signaling pathways as therapeutic targets in cancer,” International Journal of Biological Sciences, vol. 13, no. 7, pp. 815–827, 2017.
View at: Google Scholar
T. Li and J. A. Sparano, “Inhibiting Ras signaling in the therapy of breast cancer,” Clinical Breast Cancer, vol. 3, no. 6, pp. 405–416, 2003.
View at: Google Scholar
P. D. Angelini, M. F. Zacarias Fluck, K. Pedersen et al., “Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence,” Cancer Res, vol. 73, no. 1, pp. 450–458, 2013.
View at: Google Scholar
P. Lipponen, “Apoptosis in breast cancer: relationship with other pathological parameters,” Endocrine-Related Cancer, vol. 6, no. 1, pp. 13–16, 1999.
View at: Google Scholar
R. Pare, T. Yang, J. S. Shin, and C. S. Lee, “The significance of the senescence pathway in breast cancer progression,” Journal of Clinical Pathology, vol. 66, no. 6, pp. 491–495, 2013.
View at: Google Scholar
M. Parton, M. Dowsett, and I. Smith, “Studies of apoptosis in breast cancer,” BMJ, vol. 322, no. 7301, pp. 1528–1532, 2001.
View at: Google Scholar
P. G. Roy and A. M. Thompson, “Cyclin D1 and breast cancer,” Breast, vol. 15, no. 6, pp. 718–727, 1998.
View at: Google Scholar
R. L. Sutherland and E. A. Musgrove, “Cyclins and breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 9, no. 1, pp. 95–104, 2004.
View at: Google Scholar
J. E. Goldberg and K. L. Schwertfeger, “Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics,” Current Cancer Drug Targets, vol. 11, no. 9, pp. 1133–1146, 2010.
View at: Google Scholar
M. F. Mercogliano, S. Bruni, P. V. Elizalde, and R. Schillaci, “Tumor necrosis factor alpha blockade: an opportunity to tackle breast cancer,” Frontiers in Oncology, vol. 10, p. 584, 2020.
View at: Google Scholar
S. Hayashi, T. Niwa, and Y. Yamaguchi, “Estrogen signaling pathway and its imaging in human breast cancer,” Cancer Sciences, vol. 100, no. 10, pp. 1773–1778, 2009.
View at: Google Scholar
R. Nahta and R. M. O'Regan, “Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers,” Breast Cancer Research and Treatment, vol. 135, no. 1, pp. 39–48, 2012.
View at: Google Scholar
J. M. Renoir, V. Marsaud, and G. Lazennec, “Estrogen receptor signaling as a target for novel breast cancer therapeutics,” Biochemical Pharmacology, vol. 85, no. 4, pp. 449–465, 2013.
View at: Google Scholar
S. Saha Roy and R. K. Vadlamudi, “Role of estrogen receptor signaling in breast cancer metastasis,” International Journal of Breast Cancer, vol. 2012, Article ID 654698, 2012.
View at: Google Scholar
T. Saha, S. Makar, R. Swetha, G. Gutti, and S. K. Singh, “Estrogen signaling: an emanating therapeutic target for breast cancer treatment,” European Journal of Medicinal Chemistry, vol. 177, pp. 116–143, 2019.
View at: Google Scholar
G. P. Andrieu, J. S. Shafran, C. L. Smith et al., “BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response,” Cancer Letters, vol. 465, pp. 45–58, 2019.
View at: Google Scholar
S. Chretien, I. Zerdes, J. Bergh, A. Matikas, and T. Foukakis, “Beyond PD-1/PD-L1 inhibition: what the future holds for breast cancer immunotherapy,” Cancers (Basel), vol. 11, 5 pages, 2019.
View at: Google Scholar
Y. Guo, P. Yu, Z. Liu et al., “Prognostic and clinicopathological value of programmed death ligand-1 in breast cancer: a meta-analysis,” PLoS One, vol. 11, no. 5, Article ID e0156323, 2016.
View at: Google Scholar
X. Jing, S. Shao, Y. Zhang et al., “BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer,” Experimental Cell Research, vol. 392, no. 2, Article ID 112034, 2010.
View at: Google Scholar
S. Muenst, A. R. Schaerli, F. Gao et al., “Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer,” Breast Cancer Research and Treatment, vol. 146, no. 1, pp. 15–24, 2014.
View at: Google Scholar
G. B. Jang, J. Y. Kim, S. D. Cho et al., “Blockade of Wnt/beta-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype,” Scientific Reports, vol. 5, p. 12465, 2015.
View at: Google Scholar
L. P. Schwab, D. L. Peacock, D. Majumdar et al., “Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer,” Breast Cancer Research, vol. 14, no. 1, p. R6, 2012.
View at: Google Scholar
G. L. Semenza, “Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype,” The EMBO Journal, vol. 36, no. 3, pp. 252–259, 2017.
View at: Google Scholar
D. M. Gilkes and G. L. Semenza, “Role of hypoxia-inducible factors in breast cancer metastasis,” Future Oncology, vol. 9, no. 11, pp. 1623–1636, 2013.
View at: Google Scholar
R. Lamb, M. P. Ablett, K. Spence, G. Landberg, A. H. Sims, and R. B. Clarke, “Wnt pathway activity in breast cancer sub-types and stem-like cells,” PLoS One, vol. 8, no. 7, Article ID e67811, 2013.
View at: Google Scholar
N. Dey, B. G. Barwick, C. S. Moreno et al., “Wnt signaling in triple negative breast cancer is associated with metastasis,” BMC Cancer, vol. 13, p. 537, 2013.
View at: Google Scholar
S. G. Pohl, N. Brook, M. Agostino, F. Arfuso, A. P. Kumar, and A. Dharmarajan, “Wnt signaling in triple-negative breast cancer,” Oncogenesis, vol. 6, no. 4, p. e310, 2017.
View at: Google Scholar
J. R. Prosperi and K. H. Goss, “A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer,” Current Cancer Drug Targets, vol. 11, no. 9, pp. 1074–1088, 2010.
View at: Google Scholar
M. Gasco, S. Shami, and T. Crook, “The p53 pathway in breast cancer,” Breast Cancer Research, vol. 4, no. 2, pp. 70–76, 2002.
View at: Google Scholar
A. M. Mercurio, E. A. Lipscomb, and R. E. Bachelder, “Non-angiogenic functions of VEGF in breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 10, no. 4, pp. 283–290, 2005.
View at: Google Scholar
E. A. Musgrove and R. L. Sutherland, “Biological determinants of endocrine resistance in breast cancer,” Nature Reviews Cancer, vol. 9, no. 9, pp. 631–643, 2009.
View at: Google Scholar
A. S. Clark, K. West, S. Streicher, and P. A. Dennis, “Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells,” Molecular Cancer Therapeutics, vol. 1, no. 9, pp. 707–717, 2002.
View at: Google Scholar
R. Clarke, J. J. Tyson, and J. M. Dixon, “Endocrine resistance in breast cancer--An overview and update,” Molecular and Cellular Endocrinology, vol. 418, no. 3, pp. 220–234, 2015.
View at: Google Scholar
N. Eckstein, “Platinum resistance in breast and ovarian cancer cell lines,” Journal of Experimental & Clinical Cancer Research, vol. 30, p. 91, 2011.
View at: Google Scholar
M. P. Decatris, S. Sundar, and K. J. O'Byrne, “Platinum-based chemotherapy in metastatic breast cancer: current status,” Cancer Treatment Reviews, vol. 30, no. 1, pp. 53–81, 2004.
View at: Google Scholar
P. R. Pohlmann, I. A. Mayer, and R. Mernaugh, “Resistance to trastuzumab in breast cancer,” Clinical Cancer Research, vol. 15, no. 24, pp. 7479–7491, 2009.
View at: Google Scholar
C. K. Osborne and R. Schiff, “Mechanisms of endocrine resistance in breast cancer,” Annual Review of Medicine, vol. 62, pp. 233–247, 2011.
View at: Google Scholar
J. Montojo, K. Zuberi, H. Rodriguez, G. D. Bader, and Q. Morris, “GeneMANIA: fast gene network construction and function prediction for Cytoscape,” F1000Research, vol. 3, p. 153, 2014.
View at: Google Scholar
J.-H. Kim, D.-H. Kim, J.-H. You et al., “Comparison of cytotoxin and immune activities between natural and tissue cultured plant in Artemisia capillaris thunb,” Korean Journal of Medicinal Crop Science, vol. 13, no. 4, pp. 154–160, 2005.
View at: Google Scholar
J. Song, Y. Wang, M. Teng et al., “Cordyceps militaris induces tumor cell death via the caspasedependent mitochondrial pathway in HepG2 and MCF7 cells,” Molecular Medicine Reports, vol. 13, no. 6, pp. 5132–5140, 2016.
View at: Google Scholar
H. C. Wu, S. T. Chen, J. C. Chang et al., “Radical scavenging and antiproliferative effects of cordycepin-rich ethanol extract from Brown rice-cultivated Cordyceps militaris (ascomycetes) mycelium on breast cancer cell lines,” International Journal of Medicinal Mushrooms, vol. 21, no. 7, pp. 657–669, 2019.
View at: Google Scholar
M. H. Jeong, C. M. Lee, S. W. Lee et al., “Cordycepin-enriched Cordyceps militaris induces immunomodulation and tumor growth delay in mouse-derived breast cancer,” Oncology Reports, vol. 30, no. 4, pp. 1996–2002, 2013.
View at: Google Scholar
S. O. Lee, Y. J. Jeong, M. Kim, C. H. Kim, and I. S. Lee, “Suppression of PMA-induced tumor cell invasion by capillarisin via the inhibition of NF-kappaB-dependent MMP-9 expression,” Biochemical and Biophysical Research Communications, vol. 366, no. 4, pp. 1019–1024, 2008.
View at: Google Scholar
K. Amrutha, P. Nanjan, S. K. Shaji et al., “Discovery of lesser known flavones as inhibitors of NF-kappaB signaling in MDA-MB-231 breast cancer cells–a SAR study,” Bioorganic & Medicinal Chemistry Letters, vol. 24, no. 19, pp. 4735–4742, 2014.
View at: Google Scholar
H. Takemura, H. Uchiyama, T. Ohura et al., “A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 118, no. 1-2, pp. 70–76, 2009.
View at: Google Scholar
J. Yeon Park, H. Young Kim, T. Shibamoto et al., “Beneficial effects of a medicinal herb, Cirsium japonicum var. maackii, extract and its major component, cirsimaritin on breast cancer metastasis in MDA-MB-231 breast cancer cells,” Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 17, pp. 3968–3973, 2017.
View at: Google Scholar
E. M. Noh, H. J. Youn, S. H. Jung et al., “Cordycepin inhibits TPA-induced matrix metalloproteinase-9 expression by suppressing the MAPK/AP-1 pathway in MCF-7 human breast cancer cells,” International Journal of Molecular Medicine, vol. 25, no. 2, pp. 255–260, 2010.
View at: Google Scholar
D. Wang, Y. Zhang, J. Lu et al., “Cordycepin, a natural antineoplastic agent, induces apoptosis of breast cancer cells via caspase-dependent pathways,” Natural Product Communications, vol. 11, no. 1, pp. 63–68, 2016.
View at: Google Scholar
S. Choi, M. H. Lim, K. M. Kim, B. H. Jeon, W. O. Song, and T. W. Kim, “Cordycepin-induced apoptosis and autophagy in breast cancer cells are independent of the estrogen receptor,” Toxicology and Applied Pharmacology, vol. 257, no. 2, pp. 165–173, 2011.
View at: Google Scholar
D. Lee, W. Y. Lee, K. Jung et al., “The inhibitory effect of cordycepin on the proliferation of MCF-7 breast cancer cells, and its mechanism: an investigation using network pharmacology-based analysis,” Biomolecules, vol. 9, no. 9, 2019.
View at: Google Scholar
H. J. Lee, P. Burger, M. Vogel, K. Friese, and A. Bruning, “The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells,” Invest New Drugs, vol. 30, no. 5, pp. 1917–1925, 2012.
View at: Google Scholar
J. Dong, Y. Li, H. Xiao et al., “Cordycepin sensitizes breast cancer cells toward irradiation through elevating ROS production involving Nrf2,” Toxicology and Applied Pharmacology, vol. 364, pp. 12–21, 2019.
View at: Google Scholar
V. P. Androutsopoulos, K. Ruparelia, R. R. Arroo, A. M. Tsatsakis, and D. A. Spandidos, “CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells,” Toxicology, vol. 264, no. 3, pp. 162–170, 2009.
View at: Google Scholar
H. W. Zhang, J. J. Hu, R. Q. Fu et al., “Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kgamma mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells,” Scientific Reports, vol. 8, no. 1, p. 11255, 2018.
View at: Google Scholar
Y. Li, J. Hong, H. Li et al., “Genkwanin nanosuspensions: a novel and potential antitumor drug in breast carcinoma therapy,” Drug Delivery, vol. 24, no. 1, pp. 1491–1500, 2017.
View at: Google Scholar
Q. Wu, P. A. Kroon, H. Shao, P. W. Needs, and X. Yang, “Differential effects of quercetin and two of its derivatives, isorhamnetin and isorhamnetin-3-glucuronide, in inhibiting the proliferation of human breast-cancer MCF-7 cells,” Journal of Agricultural and Food Chemistry, vol. 66, no. 27, pp. 7181–7189, 2018.
View at: Google Scholar
C. Li, D. Yang, Y. Zhao et al., “Inhibitory effects of isorhamnetin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9,” Nutrition and Cancer, vol. 67, no. 7, pp. 1191–1200, 2015.
View at: Google Scholar
J. Hu, Y. Zhang, X. Jiang et al., “ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine,” Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 225, 2019.
View at: Google Scholar
A. Alvarez-Sala, A. Attanzio, L. Tesoriere, G. Garcia-Llatas, R. Barbera, and A. Cilla, “Apoptotic effect of a phytosterol-ingredient and its main phytosterol (beta-sitosterol) in human cancer cell lines,” International Journal of Food Sciences and Nutrition, vol. 70, no. 3, pp. 323–334, 2019.
View at: Google Scholar
C. Park, D. O. Moon, C. H. Ryu et al., “Beta-sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis,” Acta Pharmacologica Sinica, vol. 29, no. 3, pp. 341–348, 2008.
View at: Google Scholar
A. B. Awad, R. Roy, and C. S. Fink, “Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells,” Oncology Reports, vol. 10, no. 2, pp. 497–500, 2003.
View at: Google Scholar
A. B. Awad, A. C. Downie, and C. S. Fink, “Inhibition of growth and stimulation of apoptosis by beta-sitosterol treatment of MDA-MB-231 human breast cancer cells in culture,” International Journal of Molecular Medicine, vol. 5, no. 5, pp. 541–545, 2000.
View at: Google Scholar
A. B. Awad, S. L. Barta, C. S. Fink, and P. G. Bradford, “beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism,” Molecular Nutrition & Food Research, vol. 52, no. 4, pp. 419–426, 2008.
View at: Google Scholar
C. Azevedo, A. Correia-Branco, J. R. Araujo, J. T. Guimaraes, E. Keating, and F. Martel, “The chemopreventive effect of the dietary compound kaempferol on the MCF-7 human breast cancer cell line is dependent on inhibition of glucose cellular uptake,” Nutrition and Cancer, vol. 67, no. 3, pp. 504–513, 2015.
View at: Google Scholar
S. Y. Chien, Y. C. Wu, J. G. Chung et al., “Quercetin-induced apoptosis acts through mitochondrial- and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells,” Human & Experimental Toxicology, vol. 28, no. 8, pp. 493–503, 2009.
View at: Google Scholar
E. J. Choi and W. S. Ahn, “Kaempferol induced the apoptosis via cell cycle arrest in human breast cancer MDA-MB-453 cells,” Nutrition Research and Practice, vol. 2, no. 4, pp. 322–325, 2008.
View at: Google Scholar
C. C. Chou, J. S. Yang, H. F. Lu et al., “Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells,” Archives of Pharmacal Research, vol. 33, no. 8, pp. 1181–1191, 2010.
View at: Google Scholar
M. T. Cook, Y. Liang, C. Besch-Williford, S. Goyette, B. Mafuvadze, and S. M. Hyder, “Luteolin inhibits progestin-dependent angiogenesis, stem cell-like characteristics, and growth of human breast cancer xenografts,” Springerplus, vol. 4, p. 444, 2015.
View at: Google Scholar
M. T. Cook, Y. Liang, C. Besch-Williford, and S. M. Hyder, “Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells,” Breast Cancer (Dove Med Press), vol. 9, pp. 9–19, 2017.
View at: Google Scholar
X. H. Deng, H. Y. Song, Y. F. Zhou, G. Y. Yuan, and F. J. Zheng, “Effects of quercetin on the proliferation of breast cancer cells and expression of survivin in vitro,” Experimental and Therapeutic Medicine, vol. 6, no. 5, pp. 1155–1158, 2013.
View at: Google Scholar
J. Duo, G. G. Ying, G. W. Wang, and L. Zhang, “Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation,” Molecular Medicine Reports, vol. 5, no. 6, pp. 1453–1456, 2012.
View at: Google Scholar
G. Gao, R. Ge, Y. Li, and S. Liu, “Luteolin exhibits anti-breast cancer property through up-regulating miR-203,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 47, no. 1, pp. 3265–3271, 2019.
View at: Google Scholar
L. Huang, K. Jin, and H. Lan, “Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase,” Oncology Letters, vol. 17, no. 4, pp. 3842–3850, 2019.
View at: Google Scholar
H. Hung, “Inhibition of estrogen receptor alpha expression and function in MCF-7 cells by kaempferol,” Journal of Cellular Physiology, vol. 198, no. 2, pp. 197–208, 2004.
View at: Google Scholar
L. Jia, S. Huang, X. Yin, Y. Zan, Y. Guo, and L. Han, “Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction,” Life Sciences, vol. 208, pp. 123–130, 2018.
View at: Google Scholar
Y. Jiang, K. P. Xie, H. N. Huo, L. M. Wang, W. Zou, and M. J. Xie, “[Inhibitory effect of luteolin on the angiogenesis of chick chorioallantoic membrane and invasion of breast cancer cells via downregulation of AEG-1 and MMP-2],” Sheng Li Xue Bao, vol. 65, no. 5, pp. 513–518, 2013.
View at: Google Scholar
G. Y. Kang, E. R. Lee, J. H. Kim et al., “Downregulation of PLK-1 expression in kaempferol-induced apoptosis of MCF-7 cells,” European Journal of Pharmacology, vol. 611, no. 1-3, pp. 17–21, 2009.
View at: Google Scholar
B. W. Kim, E. R. Lee, H. M. Min et al., “Sustained ERK activation is involved in the kaempferol-induced apoptosis of breast cancer cells and is more evident under 3-D culture condition,” Cancer Biology & Therapy, vol. 7, no. 7, pp. 1080–1089, 2008.
View at: Google Scholar
M. J. Kim, J. S. Woo, C. H. Kwon, J. H. Kim, Y. K. Kim, and K. H. Kim, “Luteolin induces apoptotic cell death through AIF nuclear translocation mediated by activation of ERK and p38 in human breast cancer cell lines,” Cell Biology International, vol. 36, no. 4, pp. 339–344, 2012.
View at: Google Scholar
S. H. Kim, K. A. Hwang, and K. C. Choi, “Treatment with kaempferol suppresses breast cancer cell growth caused by estrogen and triclosan in cellular and xenograft breast cancer models,” Journal of Nutritional Biochemistry, vol. 28, pp. 70–82, 2016.
View at: Google Scholar
E. J. Lee, S. Y. Oh, and M. K. Sung, “Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells,” Food and Chemical Toxicology, vol. 50, no. 11, pp. 4136–4143, 2012.
View at: Google Scholar
G. A. Lee, K. C. Choi, and K. A. Hwang, “Kaempferol, a phytoestrogen, suppressed triclosan-induced epithelial-mesenchymal transition and metastatic-related behaviors of MCF-7 breast cancer cells,” Environmental Toxicology and Pharmacology, vol. 49, pp. 48–57, 2017.
View at: Google Scholar
Y. K. Lee, S. Y. Park, Y. M. Kim, W. S. Lee, and O. J. Park, “AMP kinase/cyclooxygenase-2 pathway regulates proliferation and apoptosis of cancer cells treated with quercetin,” Experimental & Molecular Medicine, vol. 41, no. 3, pp. 201–207, 2009.
View at: Google Scholar
C. Li, Y. Zhao, D. Yang et al., “Inhibitory effects of kaempferol on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9,” Biochemistry and Cell Biology, vol. 93, no. 1, pp. 16–27, 2015.
View at: Google Scholar
S. Li, Q. Zhao, B. Wang, S. Yuan, X. Wang, and K. Li, “Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation,” Phytotherapy Research, vol. 32, no. 8, pp. 1530–1536, 2018.
View at: Google Scholar
X. Li, N. Zhou, J. Wang et al., “Quercetin suppresses breast cancer stem cells (CD44(+)/CD24(-)) by inhibiting the PI3K/Akt/mTOR-signaling pathway,” Life Sciences, vol. 196, pp. 56–62, 2018.
View at: Google Scholar
C. H. Lin, C. Y. Chang, K. R. Lee, H. J. Lin, T. H. Chen, and L. Wan, “Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway,” BMC Cancer, vol. 15, p. 958, 2015.
View at: Google Scholar
C. W. Lin, W. C. Hou, S. C. Shen et al., “Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells,” Carcinogenesis, vol. 29, no. 9, pp. 1807–1815, 2008.
View at: Google Scholar
D. Lin, G. Kuang, J. Wan et al., “Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of beta-catenin expression,” Oncology Reports, vol. 37, no. 2, pp. 895–902, 2017.
View at: Google Scholar
B. M. Markaverich, K. Shoulars, and M. A. Rodriguez, “Luteolin regulation of estrogen signaling and cell cycle pathway genes in MCF-7 human breast cancer cells,” International Journal of Biomedical Science, vol. 7, no. 2, pp. 101–111, 2011.
View at: Google Scholar
L. T. Nguyen, Y. H. Lee, A. R. Sharma et al., “Quercetin induces apoptosis and cell cycle arrest in triple-negative breast cancer cells through modulation of Foxo3a activity,” The Korean Journal of Physiology & Pharmacology, vol. 21, no. 2, pp. 205–213, 2017.
View at: Google Scholar
S. M. Oh, Y. P. Kim, and K. H. Chung, “Biphasic effects of kaempferol on the estrogenicity in human breast cancer cells,” Archives of Pharmacal Research, vol. 29, no. 5, pp. 354–362, 2006.
View at: Google Scholar
S. H. Park, S. Ham, T. H. Kwon et al., “Luteolin induces cell cycle arrest and apoptosis through extrinsic and intrinsic signaling pathways in MCF-7 breast cancer cells,” Journal of Environmental Pathology, Toxicology, and Oncology, vol. 33, no. 3, pp. 219–231, 2014.
View at: Google Scholar
K. Phromnoi, S. Yodkeeree, S. Anuchapreeda, and P. Limtrakul, “Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids,” Acta Pharmacologica Sinica, vol. 30, no. 8, pp. 1169–1176, 2009.
View at: Google Scholar
S. Ranganathan, D. Halagowder, and N. D. Sivasithambaram, “Quercetin suppresses twist to induce apoptosis in MCF-7 breast cancer cells,” PLoS One, vol. 10, no. 10, Article ID e0141370, 2015.
View at: Google Scholar
P. S. Rao, A. Satelli, M. Moridani, M. Jenkins, and U. S. Rao, “Luteolin induces apoptosis in multidrug resistant cancer cells without affecting the drug transporter function: involvement of cell line-specific apoptotic mechanisms,” International Journal of Cancer, vol. 130, no. 11, pp. 2703–2714, 2012.
View at: Google Scholar
K. M. Reipas, J. H. Law, N. Couto et al., “Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1),” Oncotarget, vol. 4, no. 2, pp. 329–345, 2013.
View at: Google Scholar
A. Rivera Rivera, L. Castillo-Pichardo, Y. Gerena, and S. Dharmawardhane, “Anti-breast cancer potential of quercetin via the Akt/AMPK/mammalian target of rapamycin (mTOR) signaling cascade,” PLoS One, vol. 11, no. 6, Article ID e0157251, 2016.
View at: Google Scholar
G. Scambia, F. O. Ranelletti, P. Benedetti Panici et al., “Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites,” Cancer Chemotherapy and Pharmacology, vol. 28, no. 4, pp. 255–258, 1991.
View at: Google Scholar
H. S. Seo, J. M. Ku, H. S. Choi et al., “Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells,” Oncology Reports, vol. 36, no. 1, pp. 31–42, 2016.
View at: Google Scholar
A. Srinivasan, C. Thangavel, Y. Liu et al., “Quercetin regulates beta-catenin signaling and reduces the migration of triple negative breast cancer,” Including results for Mol Carcinogenesis, vol. 55, no. 5, pp. 743–756, 2015.
View at: Google Scholar
J. Q. Sui, K. P. Xie, and M. J. Xie, “Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor,” Sheng Li Xue Bao, vol. 68, no. 1, pp. 27–34, 2016.
View at: Google Scholar
D. W. Sun, H. D. Zhang, L. Mao et al., “Luteolin inhibits breast cancer development and progression in vitro and in vivo by suppressing Notch signaling and regulating MiRNAs,” Cellular Physiology and Biochemistry, vol. 37, no. 5, pp. 1693–1711, 2015.
View at: Google Scholar
S. F. Tao, H. F. He, and Q. Chen, “Quercetin inhibits proliferation and invasion acts by up-regulating miR-146a in human breast cancer cells,” Molecular and Cellular Biochemistry, vol. 402, no. 1-2, pp. 93–100, 2015.
View at: Google Scholar
L. M. Wang, K. P. Xie, H. N. Huo, F. Shang, W. Zou, and M. J. Xie, “Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERalpha in human breast cancer MCF-7 cells,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1431–1437, 2012.
View at: Google Scholar
R. Wang, L. Yang, S. Li et al., “Quercetin inhibits breast cancer stem cells via downregulation of aldehyde dehydrogenase 1A1 (ALDH1A1), chemokine receptor type 4 (CXCR4), mucin 1 (MUC1), and epithelial cell adhesion molecule (EpCAM),” Medical Science Monitor, vol. 24, pp. 412–420, 2018.
View at: Google Scholar
T. D. Way, M. C. Kao, and J. K. Lin, “Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells,” FEBS Letters, vol. 579, no. 1, pp. 145–152, 2005.
View at: Google Scholar
X. Yi, J. Zuo, C. Tan et al., “Kaempferol, a flavonoid compound from gynura medica induced apoptosis and growth inhibition in mcf-7 breast cancer cell,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 13, no. 4, pp. 210–215, 2016.
View at: Google Scholar
X. Zhao, Q. Wang, S. Yang et al., “Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer,” European Journal of Pharmacology, vol. 781, pp. 60–68, 2016.
View at: Google Scholar
L. Zhu and L. Xue, “Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis, and DNA damage in breast cancer cells,” Oncology Research, vol. 27, no. 6, pp. 629–634, 2019.
View at: Google Scholar
Y.-K. Lee, S. Y. Park, W.-S. L. Young-Min Kim, and O. Park, “Regulation of MCF-7 cell apoptosis by phytochemical quercetin through AMPK-mTOR signaling pathway,” Cancer Prevention Research, vol. 15, no. 4, pp. 320–325.
View at: Google Scholar
Y. Pandey, S. H. Mehdi, M. A. Khan, P. Bhatt, and C. Pant, “TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) mediated Apoptosis of human breast cancer cells sensitized by dietary flavonoid Kaempferol,” International Journal of Biological Sciences, vol. 5, p. 6, 2019.
View at: Google Scholar
J. Stapel, C. Oppermann, D. Richter, W. Ruth, and V. J. Briese, “Polyphenol compounds with anti-carcinogenic qualities: effects of quercetin (flavonol), chrysin (flavon), kaempferol (flavanol), naringenin (flavanon) and hesperidin (flavanoid) on in vitro breast cancer,” J Journal of Medicinal Plants Research, vol. 7, no. 29, pp. 2187–2196, 2013.
View at: Google Scholar
A. S. Sultan, M. I. Khalil, B. M. Sami, A. F. Alkhuriji, and O. J. Sadek, “Quercetin induces apoptosis in triple-negative breast cancer cells via inhibiting fatty acid synthase and β-catenin,” International Journal of Clinical and Experimental Pathology, vol. 10, no. 1, pp. 156–172, 2017.
View at: Google Scholar
S. H. Akbas, M. Timur, and T. Ozben, “The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells,” Journal of Surgical Research, vol. 125, no. 1, pp. 49–55, 2005.
View at: Google Scholar
C. T. Chiang, T. D. Way, and J. K. Lin, “Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin,” Molecular Cancer Therapeutics, vol. 6, no. 7, pp. 2127–2138, 2007.
View at: Google Scholar
G. Du, H. Lin, M. Wang et al., “Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 2, pp. 277–287, 2010.
View at: Google Scholar
G. J. Du, Z. H. Song, H. H. Lin, X. F. Han, S. Zhang, and Y. M. Yang, “Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 372, no. 3, pp. 497–502, 2008.
View at: Google Scholar
Y. W. Jeon, Y. E. Ahn, W. S. Chung, H. J. Choi, and Y. J. Suh, “Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells,” Tumor Biology, vol. 36, no. 8, pp. 6349–6359, 2015.
View at: Google Scholar
Y. W. Jeon and Y. J. Suh, “Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells,” Oncology Reports, vol. 29, no. 2, pp. 819–825, 2013.
View at: Google Scholar
M. R. Kim, H. S. Choi, J. W. Yang, B. C. Park, J. A. Kim, and K. W. Kang, “Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2163–2171, 2009.
View at: Google Scholar
S. Li, S. Yuan, Q. Zhao, B. Wang, X. Wang, and K. Li, “Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it,” Biomedicine & Pharmacotherapy, vol. 100, pp. 441–447, 2018.
View at: Google Scholar
S. Z. Li, S. F. Qiao, J. H. Zhang, and K. Li, “Quercetin increase the chemosensitivity of breast cancer cells to doxorubicin via PTEN/Akt pathway,” Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 9, pp. 1185–1189, 2015.
View at: Google Scholar
H. Liu, J. I. Lee, and T. G. Ahn, “Effect of quercetin on the anti-tumor activity of cisplatin in EMT6 breast tumor-bearing mice,” Obstetrics & Gynecology Science, vol. 62, no. 4, pp. 242–248, 2019.
View at: Google Scholar
N. Orsolic and N. Car, “Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo,” Tumor Biology, vol. 35, no. 7, pp. 6445–6454, 2014.
View at: Google Scholar
R. Sharma, L. Gatchie, I. S. Williams et al., “Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme,” Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 24, pp. 5400–5403, 2017.
View at: Google Scholar
S. H. Tu, C. T. Ho, M. F. Liu et al., “Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression,” Food Chemistry, vol. 141, no. 2, pp. 1553–1561, 2013.
View at: Google Scholar
H. Wang, L. Tao, K. Qi et al., “Quercetin reverses tamoxifen resistance in breast cancer cells,” Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology, vol. 20, no. 3, pp. 707–713, 2015.
View at: Google Scholar
M. Y. Wong and G. N. Chiu, “Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment,” Anticancer Drugs, vol. 21, no. 4, pp. 401–410, 2010.
View at: Google Scholar
M. Y. Wong and G. N. Chiu, “Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model,” Nanomedicine, vol. 7, no. 6, pp. 834–840, 2011.
View at: Google Scholar
M. Y. Yang, C. J. Wang, N. F. Chen, W. H. Ho, F. J. Lu, and T. H. Tseng, “Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3,” Chemico-Biological Interactions, vol. 213, pp. 60–68, 2014.
View at: Google Scholar
L. Zhang, F. Yang, L. Huang, A. Liu, and J. Zhang, “Luteolin enhances the antitumor activity of lapatinib in human breast cancer cells,” Biomed Res, vol. 28, no. 11, pp. 4902–4907, 2017.
View at: Google Scholar
S. Soltanian, H. Riahirad, A. Pabarja, M. R. Karimzadeh, and K. J. B. Saeidi, “Kaempferol and docetaxel diminish side population and down-regulate some cancer stem cell markers in breast cancer cell line MCF-7,” Biocell, vol. 41, no. 2&3, p. 33, 2018.
View at: Google Scholar
M. Louisa and B. Wardhani, “Quercetin improves the efficacy of sorafenib in triple negative breast cancer cells through the modulation of drug efflux transporters expressions,” International Journal of Applied Pharmaceutics, vol. 11, pp. 129–134, 2019.
View at: Google Scholar
M. L. Ackland, S. van de Waarsenburg, and R. Jones, “Synergistic antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines,” In Vivo, vol. 19, no. 1, pp. 69–76, 2005.
View at: Google Scholar
Y. L. Shih, H. C. Liu, C. S. Chen et al., “Combination treatment with luteolin and quercetin enhances antiproliferative effects in nicotine-treated MDA-MB-231 cells by down-regulating nicotinic acetylcholine receptors,” Journal of Agricultural and Food Chemistry, vol. 58, no. 1, pp. 235–241, 2009.
View at: Google Scholar
P. Knekt, J. Kumpulainen, R. Jarvinen et al., “Flavonoid intake and risk of chronic diseases,” The American Journal of Clinical Nutrition, vol. 76, no. 3, pp. 560–568, 2002.
View at: Google Scholar
U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum, “Irinotecan in the treatment of colorectal cancer: clinical overview,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1501–1518, 2001.
View at: Google Scholar

Copyright

Copyright © 2021 Ho-Sung Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1548

Downloads

1300

Citations